MDGL Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Madrigal Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$284.66 |
52 Week High | US$299.98 |
52 Week Low | US$119.76 |
Beta | -0.43 |
11 Month Change | 4.78% |
3 Month Change | 23.85% |
1 Year Change | 47.29% |
33 Year Change | 220.49% |
5 Year Change | 214.68% |
Change since IPO | 2,704.50% |
Recent News & Updates
Recent updates
Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Apr 24Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
Mar 15Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
Feb 07Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Dec 20We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Aug 05Madrigal: Buy And Hoard Before Q4 Data Readout
Aug 04Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout
Jul 08Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 11Madrigal: NASH Data In Q4 Is The Key
Apr 19We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Feb 24Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come
Jan 31Madrigal: Powerful Catalyst Approaching
Jan 09We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Nov 08We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Jul 26Madrigal Pharmaceuticals: Leading The NASH Innovation
May 05Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation
Apr 12We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth
Dec 28Madrigal Pharma: A Look At The Early MAESTRO Trial Data
Nov 27Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow
Nov 17Madrigal Pharmaceuticals EPS misses by $0.40
Nov 05Shareholder Returns
MDGL | US Biotechs | US Market | |
---|---|---|---|
7D | 0.4% | -0.3% | 2.1% |
1Y | 47.3% | 17.2% | 20.5% |
Return vs Industry: MDGL exceeded the US Biotechs industry which returned 17.2% over the past year.
Return vs Market: MDGL exceeded the US Market which returned 20.5% over the past year.
Price Volatility
MDGL volatility | |
---|---|
MDGL Average Weekly Movement | 7.4% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 14.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MDGL's share price has been volatile over the past 3 months.
Volatility Over Time: MDGL's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 376 | Bill Sibold | www.madrigalpharma.com |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. Fundamentals Summary
MDGL fundamental statistics | |
---|---|
Market cap | US$6.07b |
Earnings (TTM) | -US$444.27m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.7x
P/E RatioIs MDGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MDGL income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$444.28m |
Earnings | -US$444.27m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 07, 2024
Earnings per share (EPS) | -20.85 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 13.7% |
How did MDGL perform over the long term?
See historical performance and comparison